Lunai Bioworks Expands CNS Portfolio With $20M Acquisition

Lunai Bioworks ( (LNAI) ) just unveiled an update.

On March 24, 2026, Lunai Bioworks, Inc. entered into debt exchange agreements with three holders of its secured promissory notes to cancel about $828,770 of principal and accrued interest in exchange for 3,909,293 common shares and warrants for 1,433,621 additional shares at an implied price of $0.21, with board approval granted on March 23, 2026. The exchanges, subject to conditions including Nasdaq clearance and customary closing steps, are intended to strengthen the balance sheet by converting secured debt into equity and eliminating related security interests.

On March 26, 2026, Lunai Bioworks signed a binding $20 million Acquisition Agreement with Clemann Group, SAS to acquire blood-brain barrier delivery technology and central nervous system Alzheimer’s drug assets through Series B convertible preferred stock at a fixed $1.50 conversion price capped at 19.9% ownership. The deal, which remains subject to customary closing conditions, is expected to bolster Lunai’s CNS Alzheimer’s pipeline and broaden its ability to develop next-generation brain-penetrant therapies, potentially enhancing its competitive position in CNS drug development.

More about Lunai Bioworks

Lunai Bioworks, Inc. is an AI-driven life sciences company that advances drug discovery through an integrated platform combining clinical data, machine learning and in vivo validation to identify disease biology and develop precision therapeutics. The company focuses on central nervous system diseases and oncology, aiming to shorten development timelines and improve clinical success rates in these target markets.

Average Trading Volume: 16,159,512

Technical Sentiment Signal: Sell

Current Market Cap: $9.98M

For a thorough assessment of LNAI stock, go to TipRanks’ Stock Analysis page.